Combination therapies for treating metastatic melanoma.
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Hussein
H
Tawbi
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000556:secondary / Q000628:therapy; D003131:Combined Modality Therapy / Q000009:adverse effects / Q000379:methods; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000473:pathology* / Q000628:therapy*; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics; D016896:Treatment Outcome
D047428:Protein Kinase Inhibitors; D048493:Proto-Oncogene Proteins B-raf; D020928:Mitogen-Activated Protein Kinases